Research Topics
| S R D JohnstonSummaryAffiliation: Royal Brompton Hospital Country: UK Publications
| Collaborators
|
Detail Information
Publications
New targets for therapy in breast cancer: farnesyltransferase inhibitorsJulia Head
Department of Medicine, Royal Marsden Hospital, London, UK
Breast Cancer Res 6:262-8. 2004....- Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigationsStephen Rd Johnston
Department of Medicine, Royal Marsden Hospital, London, United Kingdom
Clin Cancer Res 11:889s-99s. 2005..This article reviews the rationale and current status of clinical trials in this area as well as the challenges that lie ahead for the development of these therapeutic combinations for breast cancer... - Fulvestrant and the sequential endocrine cascade for advanced breast cancerS Johnston
Department of Medicine Breast Unit, The Royal Marsden Hospital NHS Trust and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
Br J Cancer 90:S15-8. 2004.... - Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendationsStephen R D Johnston
Department of Medicine Breast Unit, Royal Marsden Hospital, London, UK
Cancer Invest 22:730-42. 2004..Accounting for all available data, NICE guidance supports the appropriate roles of paclitaxel, topotecan, and pegylated liposomal doxorubicin in the treatment of advanced ovarian cancer... - Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistanceS R D Johnston
Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
Endocr Relat Cancer 12:S145-57. 2005..This article reviews some of the preclinical evidence supporting this strategy, together with the current status of clinical trials in this area... - Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceStephen R D Johnston
Department of Medicine Breast Unit, The Royal Marsden NHS Trust, 233 Fulham Road, London SW3 6JJ, UK
J Steroid Biochem Mol Biol 95:173-81. 2005..This article reviews the pre-clinical rationale for this strategy and the clinical trials in this area... - Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancerStephen R D Johnston
Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
J Clin Oncol 21:2492-9. 2003..We conducted a phase II study in 76 patients with advanced breast cancer... - A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifenS R D Johnston
Cancer Research UK, Lincoln's Inn Fields, London, WC2A 3PX, UK
Cancer Chemother Pharmacol 53:341-8. 2004.... - The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signallingL A Martin
Academic Department of Biochemistry, Institute of Cancer Research, London, UK
Endocr Relat Cancer 12:1017-36. 2005..These results support the use of ICI in women with ER-positive breast cancer who have relapsed on an aromatase inhibitor... - Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experienceS Sutherland
Department of Medicine, The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Fulham Road, Chelsea and Sutton, London, UK
Br J Cancer 102:995-1002. 2010..The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab... - A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancerD D Gibbs
Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Br J Cancer 86:1379-84. 2002.... - A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancerR H De Boer
The Royal Marsden NHS Trust, London, UK
Ann Oncol 13:889-94. 2002..A 50% increase in relative dose intensity of epirubicin and cyclophosphamide is achieved, while overall treatment time is reduced by 33%... - Catheter fracture: a rare complication of totally implantable venous devicesN R Maisey
Department of Medical Oncology, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Breast 12:287-9. 2003..All patients with TIVDs should be investigated for possible catheter fracture if they develop pain over the superior anterior chest wall and/or there is difficulty or pain during aspiration or injection... - Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonistsS R D Johnston
Department of Medicine Breast Unit, Royal Marsden Hospital, London, United Kingdom
Int J Gynecol Cancer 16:543-8. 2006..Subsequent trials will be needed to see whether combinations of novel STIs are well tolerated and how they may further enhance clinical benefit in breast cancer... - Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerJ R Ross
Department of Palliative Medicine, Royal Marsden Hospital, London SW3 6JJ
BMJ 327:469. 2003..To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases... - Growth factor signalling and response to endocrine therapy: the Royal Marsden ExperienceM Dowsett
Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
Endocr Relat Cancer 12:S113-7. 2005..There is an unfortunate paucity of clinical and biological data on acquired resistance to aromatase inhibitors... - Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis
Guy s and St Thomas NHS Trust, London, UK
Lancet 373:1681-92. 2009..The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration... - A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancerR L Jones
Breast Unit, Royal Marsden NHS Trust, London, UK
Br J Cancer 100:305-10. 2009..Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules... - Platinum-based chemotherapy in triple-negative breast cancerB Sirohi
Breast Unit, Royal Marsden NHS Foundation Trust, London, UK
Ann Oncol 19:1847-52. 2008..We present our long-term results with platinum-based chemotherapy for TN breast cancer... - The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancerSacha J Howell
CRC Department of Medical Oncology, University of Manchester, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
Best Pract Res Clin Endocrinol Metab 18:47-66. 2004..029). Future clinical studies will evaluate fulvestrant in the neoadjuvant setting together with its optimal sequencing in relation to tamoxifen and other endocrine therapies in advanced disease... - A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancerHugo E R Ford
Department of Medicine, Breast Unit, Royal Marsden NHS Trust, 233 Fulham Road, SW3 6JJ, London, United Kingdom
Cancer Chemother Pharmacol 58:809-15. 2006..Although the level of myelosuppression is lower than 3-weekly regimens, this weekly regimen cannot be recommended due to the significant non-haematological toxicities associated with the treatment... - Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancerThomas E Delea
Policy Analysis Inc, 4 Davis Court, Brookline, MA 02245, USA
Am J Manag Care 12:374-86. 2006..To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen... - Fulvestrant (AstraZeneca)Stephen R D Johnston
Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, UK
Curr Opin Investig Drugs 3:305-12. 2002..Analysts at Lehman Brothers predicted in December 2001, that the product has a 90% chance of making it to market in 2002, with peak sales potential in this year of $800 million [434768]... - Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancerStephen R D Johnston
Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
J Steroid Biochem Mol Biol 106:180-6. 2007..This article reviews the rationale for these strategies, and discusses the lessons that need to be learnt if we are to successfully integrate these new drugs with aromatase inhibitors in the clinic... - The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivoLesley Ann Martin
Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB United Kingdom
Mol Cancer Ther 6:2458-67. 2007..Enhanced G1 arrest due to modulation of cell cycle regulatory proteins may be the underlying mechanism for the positive interaction between FTIs and tamoxifen... - Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancerAlexandra F Leary
Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Breast Cancer Res 9:112. 2007..This article will review the results of clinical trials of endocrine/biological combinations conducted in early and advanced breast cancer as well as provide an update on ongoing studies... - Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancerStephen R D Johnston
Departments of Medicine and Academic Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JJ, United Kingdom
Clin Cancer Res 9:524S-32S. 2003.... - Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge ConferenceSteven E Come
Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Cancer 112:673-8. 2008..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer... - Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancerStephen R D Johnston
Department of Medicine, Breast Unit, Royal Marsden Hospital NHS Trust, 233 Fulham Road, London SW3 6JJ, United Kingdom
Clin Cancer Res 12:1061s-1068s. 2006..The correlation of molecular and clinical results from these ongoing studies will be important to establish appropriate biological variables for selecting those patients who may benefit most from this combined approach... - Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statementSteven E Come
Breast Cancer Program, Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Clin Cancer Res 12:997s-1000s. 2006 - Novel systemic therapies for breast cancerSoo Lo
Department of Medicine-Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
Surg Oncol 12:277-87. 2003..As these new therapies evolve towards the clinic, the challenge to oncologists is whether their potential seen in the laboratory can be matched by further substantial improvements in clinical outcome... - Aromatase inhibitors for breast cancer: lessons from the laboratoryStephen R D Johnston
Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
Nat Rev Cancer 3:821-31. 2003 - Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft modelSimone Detre
Academic Department of Biochemistry, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, U.K
Cancer Res 63:6516-22. 2003..These results show that ARZ is an effective antagonist of E2-stimulated breast cancer growth with similar growth-inhibitory and pharmacodynamic effects to TAM in this model... - Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 11:861s-4s. 2005 - Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?Stephen R D Johnston
Department of Medicine Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK
Breast Cancer Res 7:119-30. 2005..In contrast, SERDs may have useful efficacy following aromatase inhibitors because of their unique mechanism of action, and clinical trials to determine their optimal use or sequence are ongoing... - Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivationLesley Ann Martin
Academic Department of Biochemistry, Institute of Cancer Research, London, United Kingdom
J Biol Chem 278:30458-68. 2003..These data suggest that although elevated levels of MAPK occur during LTED and influence the phenotype, this is unlikely to be the sole pathway operating to achieve adaptation... - Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statementSteven E Come
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 9:443S-6S. 2003 - Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivationLesley Ann Martin
Molecular Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Chester Beatty Laboratories, Fulham Rd, London SW3 6JB, UK
Endocr Relat Cancer 12:S75-84. 2005.... - Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivationChristina M W Chan
Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
J Steroid Biochem Mol Biol 81:333-41. 2002..Thus, the resistance of these human breast cancer cells to oestrogen-deprivation appears to be due to acquired hypersensitivity which may be explained in part by increased levels of and phosphorylated ERalpha... - Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?Stephen R D Johnston
Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London, UK
Cancer 112:710-7. 2008.... - Small molecule signal transduction inhibitors for the treatment of solid tumorsAlexandra Leary
The Royal Marsden Hospital, London, UK
Cancer Invest 25:347-65. 2007..This review will discuss the small molecule signal transduction inhibitors in various stages of development and address the strategic issues relating to clinical trial design with these novel targeted agents... - Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complexBin Chen
Robert H. Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Int J Oncol 27:327-35. 2005..We conclude that endogenous ERbeta may not play a dominant role in the modulation of the tamoxifen ERalpha complex, or in the development of tamoxifen-stimulated resistant tumor growth... - BMS-214662 (Bristol-Myers Squibb)Stephen R D Johnston
Department of Medicine Breast Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
IDrugs 6:72-8. 2003..By October 2000, preclinical investigations were ongoing in Japan. By February 2001, the drug was in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers... - Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancerStephen R D Johnston
Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
Drugs Today (Barc) 42:441-53. 2006..Parallel biomarker studies are starting to elucidate predictive molecular phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor... - Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspectiveJonathan Karnon
School of Health and Related Research, University of Sheffield, Sheffield, UK
Pharmacoeconomics 24:237-50. 2006..The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting...